NCT05101369

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: Male
• Age: 35 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To evaluate the absorption, metabolism, and excretion of 86550-106 in healthy males.

Detailed description

The purpose of this study is to determine the absorption, metabolism, and excretion of a single oral dose of 400 mg (4x100 mg tablets) of INCB086550 followed by an oral dose solution of approximately 100 μCi (3.7 MBq) \[14C\]-INCB086550 and to characterize and determine the metabolites present in plasma, urine, and, where possible, feces in healthy male participants .

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	INCB086550	INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.

Timeline

• Start date: 2022-01-21
• Primary completion: 2022-03-25
• Completion: 2022-03-25
• First posted: 2021-11-01
• Last updated: 2025-08-21

Locations

1 site across 1 country: United Kingdom